🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jesper Falkesgaard Højen

Novo Nordisk (Denmark)

ORCID: 0000-0002-2629-5391

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial”.

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

Nature Medicine(2023)10.1038/s41591-023-02547-6

N/A

1.6DataRank · unranked

85 citations

Jesper Falkesgaard Højen, Marie H. Pahus, Míriam Rosás-Umbert, Birgitte Stiksrud, James McMahon +28 more

A novel anti-human IL-1R7 antibody reduces IL-18-mediated inflammatory signaling

Journal of Biological Chemistry(2021)10.1016/j.jbc.2021.100630

N/A

0.489DataRank · unranked

25 citations

Liqiong Jiang, Karsten Beckmann, Jesper Falkesgaard Højen, Ulrich Pessara, Nicholas E. Powers +7 more

Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson’s disease

Journal of Neuroinflammation(2023)10.1186/s12974-023-02830-w

N/A

0DataRank · unranked

57 citations

Jonathan Daly, Jesper Falkesgaard Højen, Charles A. Dinarello, Jesús Amo‐Aparicio